Revance Therapeutics Management

Management criteria checks 2/4

Revance Therapeutics' CEO is Mark Foley, appointed in Oct 2019, has a tenure of 4.58 years. total yearly compensation is $10.07M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth €3.91M. The average tenure of the management team and the board of directors is 4.8 years and 4.9 years respectively.

Key information

Mark Foley

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage	7.2%
CEO tenure	4.6yrs
CEO ownership	1.1%
Management average tenure	4.8yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Foley's remuneration changed compared to Revance Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$10m	US$720k	-US$324m
Sep 30 2023	n/a	n/a	-US$414m
Jun 30 2023	n/a	n/a	-US$358m
Mar 31 2023	n/a	n/a	-US$352m
Dec 31 2022	US$7m	US$673k	-US$356m
Sep 30 2022	n/a	n/a	-US$274m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$274m
Dec 31 2021	US$7m	US$660k	-US$281m
Sep 30 2021	n/a	n/a	-US$297m
Jun 30 2021	n/a	n/a	-US$303m
Mar 31 2021	n/a	n/a	-US$292m
Dec 31 2020	US$9m	US$650k	-US$282m
Sep 30 2020	n/a	n/a	-US$249m
Jun 30 2020	n/a	n/a	-US$209m
Mar 31 2020	n/a	n/a	-US$186m
Dec 31 2019	US$18m	US$190k	-US$159m
Sep 30 2019	n/a	n/a	-US$155m
Jun 30 2019	n/a	n/a	-US$146m
Mar 31 2019	n/a	n/a	-US$143m
Dec 31 2018	US$243k	n/a	-US$143m
Sep 30 2018	n/a	n/a	-US$138m
Jun 30 2018	n/a	n/a	-US$136m
Mar 31 2018	n/a	n/a	-US$128m
Dec 31 2017	US$338k	n/a	-US$121m

Compensation vs Market: Mark's total compensation ($USD10.07M) is above average for companies of similar size in the German market ($USD1.04M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Foley (58 yo)

4.6yrs

Tenure

US$10,068,915

Compensation

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Foley	CEO & Director	4.6yrs	US$10.07m	1.06% $ 3.9m
Tobin Schilke	CFO & Principal Accounting Officer	5.5yrs	US$3.97m	0.092% $ 339.6k
Dwight Moxie	Chief Legal Officer & General Counsel	4.3yrs	US$3.53m	0.046% $ 169.2k
Jessica Serra	Head of Investor Relations & ESG	no data	no data	no data
Jeanie Herbert	Senior Director of Investor Relations & Corporate Communications	7.4yrs	no data	no data
Taryn Conway	Vice President of Marketing	5.1yrs	no data	no data
Amie Krause	Chief People Officer	1.2yrs	no data	no data
Conor Gallagher	Head of Medical Affairs & Aesthetics	6yrs	no data	no data
David Hollander	Chief Medical Officer of Global Therapeutics Franchise Lead	1.3yrs	no data	0.0058% $ 21.3k
Erica Jordan	Chief Commercial Officer	no data	no data	0.11% $ 406.4k

4.8yrs

Average Tenure

48yo

Average Age

Experienced Management: RTI's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Foley	CEO & Director	6.7yrs	US$10.07m	1.06% $ 3.9m
Angus Russell	Independent Chairman	10.2yrs	US$346.03k	0.035% $ 129.1k
Jill Beraud	Independent Director	4.9yrs	US$317.53k	0.027% $ 101.2k
Julian Gangolli	Independent Director	7.8yrs	US$305.03k	0.029% $ 106.5k
Vladimir Coric	Independent Director	1.2yrs	no data	0.0056% $ 20.5k
Olivia Ware	Independent Director	3.2yrs	US$295.03k	0.016% $ 59.0k
Carey Kolaja	Independent Director	3.2yrs	US$284.51k	0.016% $ 58.6k
Christian Nolet	Independent Director	4.8yrs	US$315.03k	0.027% $ 101.2k

4.9yrs

Average Tenure

64yo

Average Age

Experienced Board: RTI's board of directors are considered experienced (4.9 years average tenure).

Revance Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

CEO & Director recently sold €2.2m worth of stock

CEO & Director recently sold €2.1m worth of stock

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Recent updates

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Revance Therapeutics, Inc. Announces Executive Changes

Full year 2023 earnings released: US$3.83 loss per share (vs US$4.90 loss in FY 2022)

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: US$1.63 loss per share (vs US$1.17 loss in 3Q 2022)

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Second quarter 2023 earnings released: US$0.80 loss per share (vs US$0.88 loss in 2Q 2022)

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Share price stability

CEO & Director recently sold €2.2m worth of stock

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.74 loss per share (vs US$0.94 loss in 1Q 2022)

CEO & Director recently sold €2.1m worth of stock

No longer forecast to breakeven

Forecast to breakeven in 2025

Full year 2022 earnings released: US$4.90 loss per share (vs US$4.17 loss in FY 2021)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Third quarter 2022 earnings released: US$1.17 loss per share (vs US$1.10 loss in 3Q 2021)

Revance Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Revance Therapeutics, Inc. Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Revance Therapeutics, Inc. Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection in the Aesthetic Surgery Journal

Revance to Present Data from Phase 2 Juniper Clinical Trial Evaluating DAXXIFY™ (Daxibotulinumtoxina-Lanm) Injection for the Treatment of Upper Limb Spasticity At the International Congress of Parkinson and Movement Disorder Society (MDS)

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. Announces FDA Approval of DAXXIFY

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$1.07 loss in 2Q 2021)

Revance Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.94 loss per share (vs US$1.08 loss in 1Q 2021)

Revance Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Revance Therapeutics, Inc. Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Revance Therapeutics, Inc. to Present New Clinical Data on Daxibotulinumtoxin for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

High number of new directors

Revance Resubmits Biologics License Application for Daxibotulinumtoxin for Injection for Glabellar Lines to the FDA

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Claimsfiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc

Revance Therapeutics, Inc. Provides RHA® Collection Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman recently bought €89k worth of stock

Rosen Law Firm Files Class Action Lawsuit Against Revance Therapeutics, Inc

CEO & Director recently bought €458k worth of stock

Third quarter 2021 earnings released: US$1.10 loss per share (vs US$1.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$1.07 loss per share (vs US$1.12 loss in 2Q 2020)

Board Member recently sold €511k worth of stock

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from Russell 3000E Value Index

Revance Therapeutics, Inc. Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

Independent Director has left the company

Independent Director has left the company

First quarter 2021 earnings released: US$1.08 loss per share (vs US$1.15 loss in 1Q 2020)

Revance Therapeutics, Inc. to Showcase Clinical Findings of DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts at The Aesthetic Meeting 2021

Revance Therapeutics, Inc. and List Biological Laboratories, Inc. Enter into Second Addendum to the License and Service Agreement

Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

Revenue beats expectations

Full year 2020 earnings released: US$4.86 loss per share (vs US$3.67 loss in FY 2019)

Revance Announces Board Changes

New 90-day high: €25.00